Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Skye Bioscience Inc | SKYE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 12.84 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 12.84 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 11.11 - 17.6473 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 12.84 | USD |
Skye Bioscience Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 360.33M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Skye Bioscience News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SKYE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 16.22 | 17.40 | 12.5003 | 14.34 | 125,257 | -3.38 | -20.84% |
| 1 Month | 13.50 | 17.6473 | 11.11 | 14.83 | 90,363 | -0.66 | -4.89% |
| 3 Months | 13.50 | 17.6473 | 11.11 | 14.83 | 90,363 | -0.66 | -4.89% |
| 6 Months | 13.50 | 17.6473 | 11.11 | 14.83 | 90,363 | -0.66 | -4.89% |
| 1 Year | 13.50 | 17.6473 | 11.11 | 14.83 | 90,363 | -0.66 | -4.89% |
| 3 Years | 13.50 | 17.6473 | 11.11 | 14.83 | 90,363 | -0.66 | -4.89% |
| 5 Years | 13.50 | 17.6473 | 11.11 | 14.83 | 90,363 | -0.66 | -4.89% |
Skye Bioscience Description
| Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease. |
